Abstract
Fibrocystic breast disease (FBD) is a benign hormone-dependent change in breast tissue. The prevalence of FBD ranges from 30% to 60% and usually affects women aged 30 to 50 years, in most cases do not require medical intervention, while some cases can turn into premalignant histological conditions, increasing the risk of developing breast cancer. Few studies with limited cohorts have evaluated Vitex Agnus Castus (VAC) effectiveness against FBD. We evaluated the role of VAC in managing FBD using a pain measurement scale as a subjective evaluation and ultrasound as an objective evaluation.